<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172572</url>
  </required_header>
  <id_info>
    <org_study_id>W16_401#17.011</org_study_id>
    <nct_id>NCT03172572</nct_id>
  </id_info>
  <brief_title>A Pan-European Study on Minimally Invasive Versus Open Pancreatoduodenectomy in High-volume Centers</brief_title>
  <acronym>MI-PD</acronym>
  <official_title>Outcomes After Minimally Invasive or Open Pancreatoduodenectomy in High-volume Centers; a Pan-European Retrospective Propensity-score Matched Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S (Sjors) Klompmaker, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Minimally-invasive pancreatoduodenectomy (MIPD), either laparoscopic or
      robot-assisted, has been suggested as a valuable alternative to open pancreatoduodenectomy
      (OPD). The generalizability of the current literature is, however, unknown since randomized
      studies are lacking, and current data are published from few, very high volume centers and
      selection bias with a lack of case-matched series. International studies are lacking
      completely.

      OBJECTIVE: To compare outcomes of MIPD versus open pancreatoduodenectomy (OPD), in
      high-volume European pancreas centers (&gt;10 MIPDs per year, total &gt;20 PDs per year).

      METHODS: A retrospective multicenter propensity-score matched cohort study including all
      consecutive patients who underwent MIPD (or MI total pancreatectomy) between January 2012 and
      December 2016, for pancreatic head, bile duct, or duodenal cancer or cysts except chronic
      pancreatitis. Predefined electronic case report forms will be disseminated amongst
      participating centers. Participants are responsible for their own data collection. Matching
      of MIPD cases (collected from participating centers) to OPD controls (extracted from Dutch
      and German national registries) will be based on propensity scores determined by logistic
      regression including preoperative variables: year of surgery, demographics, BMI, ASA,
      comorbidities, tumor size, tumor etiology (diagnosis), and multivisceral resection. Primary
      outcome is 90-day major morbidity(Clavien-Dindo â‰¥ 3a). Secondary outcomes are 90-day
      postoperative events including: pancreatic fistula, length of hospital stay, R0
      (microscopically negative) resection margin, malignant lymph node ratio, days to adjuvant
      therapy and overall survival.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major morbidity</measure>
    <time_frame>90-days</time_frame>
    <description>Clavien-Dindo grade 3a-5 complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pancreatic fistulae</measure>
    <time_frame>90-days</time_frame>
    <description>ISGPS 2017 definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>90-days</time_frame>
    <description>length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radical resection rate</measure>
    <time_frame>90-days</time_frame>
    <description>R0/R1/R2 classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignant lymph node ratio</measure>
    <time_frame>90-days</time_frame>
    <description>Malignant/ non-malignant lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to adjuvant therapy</measure>
    <time_frame>90-days</time_frame>
    <description>Resection to adjuvant chemo(-radio) therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>90-days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Pancreas Cyst</condition>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Indication for surgery</arm_group_label>
    <description>Solid neoplasms</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimally invasive pancreatoduodenectomy</intervention_name>
    <description>Laparoscopic, robot-assisted, or hybrid resection</description>
    <arm_group_label>Indication for surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open pancreatoduodenectomy</intervention_name>
    <description>Open resection</description>
    <arm_group_label>Indication for surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cases (minimally-invasive pancreatoduodenectomy) will be retrieved from participating
        high-volume centers (2012 and 2017).

        Controls (open pancreatoduodenectomy) will be retrieved from German and Dutch
        population-based pancreatic surgery registries (2015-2017).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for open or minimally invasive pancreatoduodenectomy

          -  Pancreatic head, bile duct, or duodenal cancer or cysts

        Exclusion Criteria:

          -  Chronic pancreatitis without suspected solid tumor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sjors Klompmaker</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.e-mips.org/mipd/</url>
    <description>Consortium Website</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>S (Sjors) Klompmaker, MD</investigator_full_name>
    <investigator_title>PhD Candidate</investigator_title>
  </responsible_party>
  <keyword>minimally invasive surgical procedures</keyword>
  <keyword>pancreas surgery</keyword>
  <keyword>pancreatoduodenectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Cyst</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

